Cisplatin/epinephrine injectable gel

Drugs and Aging

Volumn 18, Issue 10, 2001, Pages 787-793

  Malhotra, Harinder ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CISPLATIN;

ANTINEOPLASTIC ACTIVITY; CANCER PALLIATIVE THERAPY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEVER; GEL; HEAD AND NECK CANCER; HUMAN; METASTASIS; NAUSEA; PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; SOLID TUMOR; TUMOR VOLUME; VASOCONSTRICTION; VOMITING;

EID: 0035211525     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118100-00007     Document Type: Review

References (5)

1. Kanekal S, Sahai A, Yu NY, et al. Rational design and development of a cisplatin/epinephrine injectable gel for intralesional treatment of accessible tumors: from preclinical models to clinical outcome [abstract]. Ann Oncol 1996; 7 Suppl. 1: 136
2. Kitchell BE, Brown DM, Luck EE, et al. Intralesional implant for treatment of primary oral malignant melanoma in dogs. J Am Vet Med Assoc 1994 January 15; 204 (2): 229-36
3. Davidson BS, Izzo F, Cromeens DM, et al. Collagen matrix cisplatin prevents local tumor growth after margin-positive resection. J Surg Res 1995; 58: 618-24
4. Yu N, Peña R, Patawaran M, et al. Increased local tumor control and improved survival rate in mice with cisplatin by combining intratumoral and systemic routes of administration [abstract no. 3906]. Proceedings of the American Association for Cancer Research 1999 Mar; 40: 592
5. Ning S, Yu N, Brown DM, et al. Radiosensitization by intratumoral administration of cisplatin in a sustained-release delivery system. Radiother Oncol 1999; 50: 215-23